Detalles de la búsqueda
1.
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
N Engl J Med
; 390(17): 1560-1571, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587254
2.
CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction.
Arterioscler Thromb Vasc Biol
; 43(6): 855-869, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36994730
3.
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Curr Atheroscler Rep
; 24(7): 585-597, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35524914
4.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Am Heart J
; 231: 121-127, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33065120
5.
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.
Br J Clin Pharmacol
; 87(6): 2558-2571, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33217027
6.
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
Am Heart J
; 208: 81-90, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30580130
7.
Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
Am Heart J
; 181: 130-136, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27823684
8.
Targeting lipoprotein (a): an evolving therapeutic landscape.
Curr Atheroscler Rep
; 17(5): 502, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25736345
9.
Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice.
Del Med J
; 87(8): 238-43, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26402926
10.
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
J Am Coll Cardiol
; 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38588930
11.
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction.
Eur Heart J Cardiovasc Pharmacother
; 9(4): 387-398, 2023 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36787889
12.
The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction.
Am Heart J
; 163(4): 705-13, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22520538
13.
Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity.
J Am Heart Assoc
; 11(8): e024754, 2022 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35411789
14.
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
J Cardiovasc Pharmacol Ther
; 27: 10742484221121507, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36282079
15.
Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.
Clin Transl Sci
; 15(10): 2331-2341, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35933730
16.
Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis.
Front Cardiovasc Med
; 8: 774418, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34966797
17.
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
Arterioscler Thromb Vasc Biol
; 29(1): 140-6, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18988892
18.
CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction.
J Am Heart Assoc
; 13(9): e033541, 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38700008
19.
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.
J Clin Pharmacol
; 59(3): 427-436, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30452776
20.
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.
Clin Pharmacol Drug Dev
; 8(5): 628-636, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30240132